Understanding
tumor-specific metabolism under
hypoxia is important to find novel targets for
antitumor drug design. Here we found that
tumor cells expressed higher levels of cytosolic
acetyl-CoA synthetase (ACSS2) under
hypoxia than normoxia. Knockdown of ACSS2 by RNA interference (RNAi) in
tumor cells enhanced
tumor cell death under long-term
hypoxia in vitro. Our data also demonstrated that the ACSS2 suppression slowed
tumor growth in vivo. These findings showed that ACSS2 plays a significant role in
tumor cell survival under
hypoxia and that ACSS2 would be a potential target for
tumor treatment. Furthermore, we found that
tumor cells excreted
acetate and the quantity increased under
hypoxia: the pattern of
acetate excretion followed the expression pattern of ACSS2. Additionally, the ACSS2 knockdown led to a corresponding reduction in the
acetate excretion in
tumor cells. These results mean that ACSS2 can conduct the reverse reaction from
acetyl-CoA to
acetate in
tumor cells, which indicates that ACSS2 is a bi-directional
enzyme in
tumor cells and that ACSS2 might play a buffering role in
tumor acetyl-CoA/
acetate metabolism.